Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Los Angeles, California--(Newsfile Corp. - May 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teladoc announced its first quarter 2022 financial results on April 27,...

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $100,000 to Contact the Firm

Foot Locker

Wynn Resorts

These stocks to avoid are the type of securities that get crushed when inflation is running at unsustainable levels. The post What Are the Worst Investments During Inflation?

What Are the Worst Investments During Inflation? 3 Stocks to Avoid.

Coupang

DraftKings

Lucid Group

Palantir Technologies

Riot Blockchain

Risky stocks or high-beta stocks that have corrected sharply in the last few months. These stocks are attractive trading bets.

7 Risky Stocks That Are Worth Betting On

Align Technology

Amazon

Long-term investors still have a lot to like about these stocks.

These 3 Growth Stocks Got Pummeled Last Week: Are They Buys Now?

Teladoc has some issues to sort through but this could ultimately amount to a tremendous buy opportunity for a stock with a healthy long-term outlook.

It's Time to Book an Appointment for Teladoc Stock

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) on behalf of Teladoc stockholders. Our investigation concerns whether Teladoc has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 27, 2022, Teladoc reported first quarter financial results

TELADOC ALERT: Bragar Eagel & Squire, P.C. is Investigating Teladoc Health, Inc. on Behalf of Teladoc Stockholders and Encourages Investors to Contact the Firm

Some investors are seeing last week's share-price drop as this week's buying opportunity.

Why Teladoc Stock Is Up Today

"We do believe that Teladoc's long-term competitive position and product differentiation are unmatched, gearing it for superior growth," Ark said.

Here's why Cathie Wood's Ark Invest is still bullish on Teladoc after the stock plunged 50%

The stock plunged after disappointing news.

Teladoc: Buy, Sell, or Hold After the 40% Drop?

The only question is which group of investors is making a mistake.

Are Investors Dead Wrong About Teladoc? Absolutely.

Here's the Silver Lining in Teladoc's Dark Cloud

Shares of Teladoc Health, Inc. (NYSE:TDOC) plunged more than 40% after it reported a net loss of $6.67 billion in the first quarter of 2022. The loss came at the back of a $6.6 billion non-cash goodwill impairment charge.

Should you buy Teladoc stock after the post-earnings dip?

Shares of Teladoc Health Inc (NYSE: TDOC) have been in a freefall this year, now down roughly 65% for the year. Still, who continues to see value in the world's largest telemedicine company is Cathie Wood.

Cathie Wood is still buying Teladoc shares: here's why

NCR Corporation

Limelight Networks

Smart investors buy great companies when their stocks are cheap. This looks like three of those opportunities.

Teladoc, Limelight, and NCR Are Bouncing Back Today (but They Still Look Cheap)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Teladoc investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities la

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Teladoc Health, Inc. (TDOC) on Behalf of Investors

Despite falling by over 40% yesterday, Cathie Wood's Ark Invest reported purchasing an additional 609,665 shares of TDOC stock. The post Cathie Wood Bought Teladoc (TDOC) Stock on the Dip.

Cathie Wood Bought Teladoc (TDOC) Stock on the Dip. Here's Why.

Ark Invest's ace stock picker is catching a falling scalpel, but the prognosis isn't as grim as you think.

Cathie Wood Is Buying Teladoc Stock; Maybe You Should, Too

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) investors concerning the Company's possible violations of federal securities laws. On April 27, 2022, Teladoc released its first quarter 2022 financial results, reporting revenue of $565.4 million – $3.23 million less than consensus estimates – and “[n]et loss per share of $41.58, primarily driven by [a] non-cash goodwill impairmen

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Teladoc Health, Inc. (TDOC) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). The investigation concerns whether Teladoc has violated the federal securities laws and/or engaged in other unlawful business practices. Teladoc is a global provider of virtual care, transforming the access, cost, and quality dynamics of health care delivery. On April 27, 2022 Teladoc reported financial results for the three mon

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Teladoc Health, Inc. (TDOC) Investors

TDOC stock fell into contentious levels with levels from the IPO days. Initiating starter positions now makes a bit of speculative sense.

Teladoc Stock Is Not as Toxic as It Seems

Ford, Amazon wrote-down stakes in Rivian. Google, Microsoft said equity bets lost value.

The market just posted an unhealthy AOL-Time Warner bubble comparison

Shareholders have seen a play in three acts: promotion, arrogance, and denial.

5 Charts That Tell the Story of Teladoc

Following extreme bullishness from management, the company not only missed Q1 2022 earnings but also slashed guidance, giving it a bit of a credibility issue. A lot of competition exists, margin compression, and revenue growth is stalling.

Teladoc: Simply Horrific

ARK Fintech Innovation ETF

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Web x.0 ETF

Shares of the telemedicine provider were cut in half on Thursday, pressuring ARKK and other ETFs.

News for Teladoc Stock (TDOC)